2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Immunotherapy IMMUNOTHERAPY-UK (此期刊被最新的JCR期刊SCIE收录) LetPub评分 6.4
50人评分
我要评分
声誉 7.6 影响力 5.0 速度 8.5 | |||||||||||||||||||||||||
期刊ISSN | 1750-743X | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
E-ISSN | 1750-7448 | |||||||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 2.7 点击查看影响因子趋势图 | |||||||||||||||||||||||||
实时影响因子 | 截止2024年10月29日:1.704 | |||||||||||||||||||||||||
2023-2024自引率 | 3.70%点击查看自引率趋势图 | |||||||||||||||||||||||||
五年影响因子 | 2.9 | |||||||||||||||||||||||||
JCI期刊引文指标 | 0.42 | |||||||||||||||||||||||||
h-index | 37 | |||||||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||
期刊官方网站 | https://www.futuremedicine.com/loi/imt | |||||||||||||||||||||||||
期刊投稿网址 | https://mc04.manuscriptcentral.com/fm-imt | |||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Immunotherapy的语言要求,还能让Immunotherapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Immunotherapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||||||
通讯方式 | FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB | |||||||||||||||||||||||||
出版商 | Future Medicine Ltd. | |||||||||||||||||||||||||
涉及的研究方向 | 医学-免疫学 | |||||||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||
出版周期 | Bimonthly | |||||||||||||||||||||||||
出版年份 | 0 | |||||||||||||||||||||||||
年文章数 | 144点击查看年文章数趋势图 | |||||||||||||||||||||||||
Gold OA文章占比 | 19.84% | |||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 75.00% | |||||||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:3区
| |||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1750-743X%5BISSN%5D | |||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 较慢,6-12周 | |||||||||||||||||||||||||
平均录用比例 | 网友分享经验: 较易 | |||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Immunotherapy顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Establishment of humanized mice and its application progress in cancer immunotherapy Author: Ding, Tianlong; Yu, Yang; Pan, Xiaoyuan; Chen, Hao Journal: IMMUNOTHERAPY. 2023; Vol. , Issue , pp. -. DOI: 10.2217/imt-2022-0148 PubMed DOI |
2. | Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy Author: Xu, Tongpeng; Wang, Chen; Chen, Xiaomei; Bai, Jian; Wang, Enxiu; Sun, Ming Journal: IMMUNOTHERAPY. 2023; Vol. 14, Issue 18, pp. 1457-1466. DOI: 10.2217/imt-2022-0171 PubMed DOI |
3. | Application of immune checkpoint inhibitors in immunotherapy for gastric cancer Author: Wu, Yi-Xiang; Zhou, Xiao-Yu; Wang, Jian-Qi; Chen, Gao-Min; Chen, Jin-Xu; Wang, Rong-Chang; Huang, Jiong-Qiang; Chen, Jing-Song Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 2, pp. 101-115. DOI: 10.2217/imt-2022-0080 PubMed DOI |
4. | A new perspective on the potential application of RIPK1 in the treatment of sepsis Author: Wang, Xuesong; Chai, Yan; Guo, Zhe; Wang, Ziyi; Liao, Haiyan; Wang, Ziwen; Wang, Zhong Journal: IMMUNOTHERAPY. 2022; Vol. 15, Issue 1, pp. 43-56. DOI: 10.2217/imt-2022-0219 PubMed DOI |
5. | Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor Author: Zhang, Yingfang; Zhang, Min; Zhang, Jing; Zhao, Kelei; Yuan, Xiaohan; Di, Wenyu; Liu, Yanting; Lu, Ping Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 1, pp. 27-33. DOI: 10.2217/imt-2022-0130 PubMed DOI |
6. | A case of late and lethal Trousseau's syndrome induced by pembrolizumab in lung adenocarcinoma Author: Cheng, Yajie; Ouyang, Wen; Jie, Chen; Zhang, Junhong; Yu, Jing; Xie, Conghua Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 2, pp. 71-75. DOI: 10.2217/imt-2022-0018 PubMed DOI |
7. | Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes Author: Zhang, Hui; Jiang, Da; Meng, Erhong; Zhao, Meng; Niu, Beifang Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 1, pp. 17-25. DOI: 10.2217/imt-2021-0259 PubMed DOI |
8. | Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient Author: Gao, Song; Wang, Jiaqian; Zhu, Zhongzheng; Fang, Juemin; Zhao, Yu; Liu, Zhuqing; Qin, Huanlong; Wei, Yuquan; Xu, Heng; Dan, Xu; Yang, Li; Xu, Qing Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 2, pp. 57-70. DOI: 10.2217/imt-2021-0339 PubMed DOI |
9. | Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis Author: Huo, Gengwei; Liu, Wenjie; Zhang, Sipei; Chen, Peng Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 3, pp. 189-207. DOI: 10.2217/imt-2022-0140 PubMed DOI |
10. | FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma Author: Zhang, Jingtao; Li, Haitao; Guo, Minghao; Zhang, Jing; Zhang, Guangming; Sun, Ning; Feng, Yuyuan; Cui, Wenqiang; Xu, Fei Journal: IMMUNOTHERAPY. 2023; Vol. 15, Issue 4, pp. 235-252. DOI: 10.2217/imt-2022-0195 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室